Overview

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Status:
Completed
Trial end date:
2018-02-06
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC